• AC Immune released interim 12-month results from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer’s disease.
• The first three patient cohorts showed ACI-24 was generally safe and well tolerated, with no ARIA-E signals reported.
• Antibody responses were observed across all tested dose levels, supporting a dose-response effect.
• A fourth cohort has started to test an added adjuvant intended to strengthen immune responses for potentially greater plaque removal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300700OMX_____CNEWS_EN_GNW1001210321_en) on June 30, 2026, and is solely responsible for the information contained therein.